BioSyent logo

BioSyent(OTC) BIOYF

Market Cap$134.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+2,249%
5 Year+127%
1 Year+44%
1 Month+4%
$11.89
+0.08%
+0.01Today
BioSyent last closing stock price
MetricPriceDate
Last closeUSD 11.882026-10-08
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.3%USD 11.502026-10-01
1 month+4.19%USD 11.402026-09-08
3 month+15.97%USD 10.242026-07-10
Year to date+26.16%USD 9.422025-12-30
1 year+43.63%USD 8.272025-10-08
3 year+114.51%USD 5.542023-10-09
5 year+126.51%USD 5.242021-10-08
Since inception+2,248.81%USD 0.512012-06-01

BioSyent Financials at a Glance

Market Cap

$134.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$55.71M

Net Income (TTM)

CA$9.87M

EPS (TTM)

$0.62

P/E Ratio

18.82

Dividend

$0.16

Beta (Volatility)

0.19 (Low)

Price

$11.89

Volume

600

Open

$11.89

Previous Close

$11.88

Daily Range

$11.89 - $11.89

52-Week Range

$7.63 - $12.41

Estimated Earnings Date

Nov 19, 2026

BIOYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a healthcare company focused on acquiring, developing, and selling pharmaceutical products in Canada and internationally. The company specializes in addressing various medical needs, particularly in the areas of iron deficiency anemia, hormone replacement therapy, and women's health.

Products and Services
  • FeraMAX Pd Therapeutic 150 for iron deficiency anemia treatment
  • Tibella, a hormone replacement therapy product
  • Inofolic, addressing symptoms of polycystic ovarian syndrome
Growth Outlook
  • Recent quarterly revenue reached CAD 19.88 million, a significant increase
  • Trailing twelve months (TTM) revenue shows consistent growth trends
  • Strong product pipeline supports future expansion in healthcare markets
Financial Highlights
  • Net income for Q2 2026 was CAD 2.85 million, reflecting robust profitability
  • TTM gross profit margin stands at 70.2%, indicating strong operational efficiency
  • Current ratio of 2.07 suggests solid liquidity position for future investments
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products that cater to critical health needs. The company's focus on iron deficiency anemia and women's health positions it well in a growing market. Recent financial performance indicates a strong upward trajectory, with significant revenue growth and profitability. The solid gross profit margin and healthy liquidity ratios further enhance the company's financial stability, making it an attractive option for potential investors interested in the healthcare sector.
AI Generated • Oct 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

BIOYF Financials

Key Financial Metrics (TTM)

Gross Margin

70.21%

Operating Margin

23.21%

Net Income Margin

17.73%

Return on Equity

22.92%

Return on Capital

26.74%

Return on Assets

16.32%

Earnings Yield

5.31%

Dividend Yield

1.31%

Payout Ratio

24.01%

Stock Overview

Market Cap

$134.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.31M

Volume

600

Avg. Volume

1.50K

Financials (TTM)

Gross Profit

CA$39.11M

Operating Income

CA$12.93M

EBITDA

CA$15.13M

Operating Cash Flow

CA$12.10M

Capital Expenditure

-CA$298.71K

Free Cash Flow

CA$11.80M

Cash & ST Invst.

CA$8.95M

Total Debt

CA$3.14M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 21,450,330-6.0%
20232023-12-31CAD 23,405,6519.1%
20242024-12-31CAD 25,570,7159.3%
20252025-12-31CAD 30,811,08920.5%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3144.3%
Q22026-06-3042.6%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.33-14.1%
20232023-12-31CAD 0.3917.6%
20242024-12-31CAD 0.4514.3%
20252025-12-31CAD 0.5624.7%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%
Q22026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$19.88M

+95.3%

Gross Profit

CA$12.93M

+63.4%

Gross Margin

65.02%

N/A

Market Cap

$134.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$188.96K

N/A

Employees

711

N/A

Net Income

CA$2.85M

+41.3%

EBITDA

CA$4.98M

+67.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$8.95M

-56.1%

Total Debt

CA$3.14M

+233.5%

Accounts Receivable

CA$6.77M

+37.6%

Inventory

CA$10.75M

+121.1%

Long Term Debt

CA$699.07K

-4.9%

Short Term Debt

CA$2.44M

+1079.7%

Return on Assets

16.32%

N/A

Return on Invested Capital

27.70%

N/A

Free Cash Flow

CA$2.54M

-26.0%

Operating Cash Flow

CA$2.55M

-26.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EBM.VEastwood Bio-Medical Canada Inc.
CA$1.70-3.41%
MDP.TOMedexus Pharmaceuticals Inc.
CA$4.84-3.01%
CSCI.TOCOSCIENS Biopharma Inc.
CA$9.60-2.93%
CPH.TOCipher Pharmaceuticals Inc.
CA$13.66+0.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$5.99+54.79%
TAT&T
$22.72-7.63%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.12-1.98%
SPCXSpace Exploration Technologies
$164.43+2.40%

Questions About BIOYF

What is the current price of BioSyent?

BioSyent is trading at $11.89 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between $7.63 and $12.41.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$2.21M.

How much cash does BioSyent have on hand?

BioSyent reported CA$3.65M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.31%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services